NCT02129673View on ClinicalTrials.gov

A Phase 1/2 Multicenter, Randomized, Study to Evaluate the Safety and Efficacy of VS101 Subconjunctival Latanoprost Insert in Subjects With Open-Angle Glaucoma or Ocular Hypertension

PHASE1/PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 31, 2014

Primary Completion Date

May 31, 2017

Study Completion Date

August 31, 2017

Conditions

Open Angle GlaucomaOcular Hypertension

Interventions

DRUG

VS101 Insert Dose A

Sustained release of latanoprost into the eye

DRUG

VS101 Insert Dose B

Sustained release of latanoprost into the eye

DRUG

VS101 Insert Dose C

Sustained release of latanoprost into the eye

DRUG

Latanoprost 0.005% eye drops

Latanoprost 0.005% eye drops administered once daily on the eye

Trial Locations (1)

Unknown

Speciality Eyecare Centre, Bellevue

All Listed Sponsors

lead

ViSci Ltd.

INDUSTRY

NCT02129673 - A Phase 1/2 Multicenter, Randomized, Study to Evaluate the Safety and Efficacy of VS101 Subconjunctival Latanoprost Insert in Subjects With Open-Angle Glaucoma or Ocular Hypertension | Biotech Hunter | Biotech Hunter